Dare Bioscience Stock Price, News & Analysis (NASDAQ:DARE)

$2.23 -0.03 (-1.33 %)
(As of 01/22/2018 04:00 PM ET)
Previous Close$2.26
Today's Range$2.20 - $2.35
52-Week Range$2.11 - $35.80
Volume9,889 shs
Average Volume25,179 shs
Market Capitalization$13.36 million
P/E Ratio-0.99
Dividend YieldN/A
Beta2.45

About Dare Bioscience (NASDAQ:DARE)

Dare Bioscience logoDare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorBio Therapeutic Drugs
SymbolNASDAQ:DARE
CUSIPN/A
Phone+1-858-7699145

Debt

Debt-to-Equity RatioN/A
Current Ratio12.51%
Quick Ratio12.51%

Price-To-Earnings

Trailing P/E Ratio-0.991111111111111
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$760,000.00
Price / Sales17.75
Cash FlowN/A
Price / CashN/A
Book Value$4.78 per share
Price / Book0.47

Profitability

Trailing EPS($2.25)
Net Income$-39,300,000.00
Net MarginsN/A
Return on Equity-228.18%
Return on Assets-126.97%

Miscellaneous

Employees19
Outstanding Shares6,050,000

Dare Bioscience (NASDAQ:DARE) Frequently Asked Questions

What is Dare Bioscience's stock symbol?

Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."

How were Dare Bioscience's earnings last quarter?

Dare Bioscience Inc (NASDAQ:DARE) released its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.08. View Dare Bioscience's Earnings History.

Who are some of Dare Bioscience's key competitors?

Who are Dare Bioscience's key executives?

Dare Bioscience's management team includes the folowing people:

  • Roger L. Hawley, Independent Chairman of the Board (Age 63)
  • Sabrina Martucci Johnson, President, Chief Executive Officer, Secretary, Director
  • Gregg D. Beloff J.D., Principal Financial Officer (Age 48)
  • Lisa Walters-Hoffert, Chief Financial Officer
  • Jame O'Neill, Principal Accounting Officer, Controller, Assistant Treasurer (Age 52)
  • William H. Rastetter Ph.D., Lead Independent Director (Age 68)
  • Steve E. Hall Ph.D., Independent Director (Age 60)
  • Susan L. Kelley M.D., Independent Director (Age 62)
  • Robin J. Steele J.D., Independent Director (Age 58)

How do I buy Dare Bioscience stock?

Shares of Dare Bioscience can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dare Bioscience's stock price today?

One share of Dare Bioscience stock can currently be purchased for approximately $2.23.

How big of a company is Dare Bioscience?

Dare Bioscience has a market capitalization of $13.36 million and generates $760,000.00 in revenue each year. The biotechnology company earns $-39,300,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Dare Bioscience employs 19 workers across the globe.

How can I contact Dare Bioscience?

Dare Bioscience's mailing address is 11119 N Torrey Pines Rd Ste 200, LA JOLLA, CA 92037-1028, United States. The biotechnology company can be reached via phone at +1-858-7699145 or via email at [email protected]


MarketBeat Community Rating for Dare Bioscience (DARE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  94 (Vote Underperform)
Total Votes:  265
MarketBeat's community ratings are surveys of what our community members think about Dare Bioscience and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dare Bioscience (NASDAQ:DARE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/ABuyBuy
Consensus Rating Score: N/AN/A3.002.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$6.00$3.00
Price Target Upside: N/AN/A757.14% upside328.57% upside

Dare Bioscience (NASDAQ:DARE) Consensus Price Target History

Price Target History for Dare Bioscience (NASDAQ:DARE)

Dare Bioscience (NASDAQ:DARE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2016Canaccord GenuityReiterated RatingBuy$6.00N/AView Rating Details
10/23/2016Roth CapitalReiterated RatingBuy$2.50N/AView Rating Details
10/19/2016Leerink SwannReiterated RatingMarket Perform$1.50N/AView Rating Details
8/30/2016BarclaysLower Price TargetOverweight$5.00 -> $2.00N/AView Rating Details
8/18/2016WedbushDowngradeOutperform -> NeutralN/AView Rating Details
8/18/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
3/9/2016JPMorgan Chase & Co.Boost Price TargetMarket Outperform$9.00 -> $16.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $9.00N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Dare Bioscience (NASDAQ:DARE) Earnings History and Estimates Chart

Earnings by Quarter for Dare Bioscience (NASDAQ:DARE)

Dare Bioscience (NASDAQ DARE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($1.42)ViewN/AView Earnings Details
5/12/2017Q1 2017($3.10)($2.20)ViewN/AView Earnings Details
11/3/2016Q3 2016($4.30)($3.60)ViewN/AView Earnings Details
8/4/2016Q216($0.48)($0.40)ViewN/AView Earnings Details
5/2/2016Q116($0.43)($0.49)ViewN/AView Earnings Details
3/10/2016Q415($0.41)($0.39)ViewListenView Earnings Details
11/16/2015Q315($0.41)($0.39)ViewListenView Earnings Details
8/6/2015Q215($0.40)($0.37)ViewN/AView Earnings Details
5/6/2015Q1 2015($4.50)($4.10)ViewN/AView Earnings Details
3/19/2015Q4 2014($0.36)($0.37)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.32)($0.28)ViewN/AView Earnings Details
8/12/2014Q2 2014($0.36)($0.34)$0.03 millionViewN/AView Earnings Details
5/27/2014Q1 2014($3.52)($3.70)$0.05 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Dare Bioscience (NASDAQ:DARE) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Dare Bioscience (NASDAQ:DARE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Dare Bioscience (NASDAQ DARE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.60%
Institutional Ownership Percentage: 8.12%
Insider Trades by Quarter for Dare Bioscience (NASDAQ:DARE)

Dare Bioscience (NASDAQ DARE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/22/2016David R WaltDirectorBuy2,291$2.08$4,765.28166,900View SEC Filing  
2/18/2016David R. WaltDirectorBuy8,960$2.10$18,816.00165,200View SEC Filing  
2/16/2016David R. WaltDirectorBuy8,811$2.00$17,622.00156,240View SEC Filing  
2/11/2016David R. WaltDirectorBuy8,850$2.05$18,142.50147,429View SEC Filing  
2/9/2016David R. WaltDirectorBuy9,000$2.15$19,350.00138,579View SEC Filing  
2/5/2016David R. WaltDirectorBuy8,563$2.30$19,694.90129,579View SEC Filing  
2/3/2016David R. WaltDirectorBuy8,413$2.32$19,518.16121,016View SEC Filing  
2/1/2016David R. WaltDirectorBuy5,700$2.38$13,566.00112,603View SEC Filing  
1/28/2016David R. WaltDirectorBuy9,000$2.46$22,140.00106,903View SEC Filing  
1/26/2016David R. WaltDirectorBuy8,800$2.39$21,032.0097,903View SEC Filing  
1/25/2016David R. WaltDirectorBuy4,500$2.35$10,575.0097,903View SEC Filing  
1/22/2016David R. WaltDirectorBuy9,000$2.28$20,520.0089,103View SEC Filing  
1/20/2016David R. WaltDirectorBuy8,900$2.43$21,627.0080,103View SEC Filing  
1/15/2016David R. WaltDirectorBuy8,572$2.53$21,687.1671,203View SEC Filing  
1/13/2016David R. WaltDirectorBuy8,684$2.79$24,228.3662,631View SEC Filing  
1/11/2016David R. WaltDirectorBuy8,855$2.87$25,413.8553,947View SEC Filing  
1/7/2016David R. WaltDirectorBuy8,800$2.95$25,960.0045,092View SEC Filing  
1/5/2016David R. WaltDirectorBuy8,801$3.03$26,667.0336,292View SEC Filing  
11/30/2015David R WaltDirectorBuy5,374$3.25$17,465.5017,491View SEC Filing  
11/27/2015David R. WaltDirectorBuy12,117$3.32$40,228.4412,117View SEC Filing  
4/7/2015Cvf, LlcMajor ShareholderBuy333,333$6.00$1,999,998.00View SEC Filing  
4/15/2014Alan L CraneDirectorBuy1,470,582$7.00$10,294,074.00View SEC Filing  
4/15/2014Eli & Co LillyMajor ShareholderBuy733,445$7.00$5,134,115.00View SEC Filing  
4/15/2014Lux Capital Management, LlcInsiderBuy106,224$7.00$743,568.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dare Bioscience (NASDAQ DARE) News Headlines

Source:
DateHeadline
Dare Bioscience (DARE) vs. The Competition Head to Head ComparisonDare Bioscience (DARE) vs. The Competition Head to Head Comparison
www.americanbankingnews.com - January 13 at 9:36 PM
Contrasting Dare Bioscience (DARE) & Its CompetitorsContrasting Dare Bioscience (DARE) & Its Competitors
www.americanbankingnews.com - January 11 at 8:18 AM
Form 8-K Dare Bioscience, Inc. For: Dec 29 - StreetInsider.comForm 8-K Dare Bioscience, Inc. For: Dec 29 - StreetInsider.com
www.streetinsider.com - January 5 at 9:02 AM
Cerulean Pharma (DARE) vs. Its Rivals Head to Head AnalysisCerulean Pharma (DARE) vs. Its Rivals Head to Head Analysis
www.americanbankingnews.com - December 27 at 10:00 AM
Reviewing Cerulean Pharma (DARE) & Its PeersReviewing Cerulean Pharma (DARE) & Its Peers
www.americanbankingnews.com - December 17 at 1:28 PM
Cerulean Pharma (DARE) Upgraded by ValuEngine to "Sell"Cerulean Pharma (DARE) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - December 9 at 12:08 PM
Who Are The Major Shareholders Of Daré Bioscience Inc (DARE)?Who Are The Major Shareholders Of Daré Bioscience Inc (DARE)?
finance.yahoo.com - December 9 at 8:57 AM
Daré Bioscience, Inc. to Present at the LD Micro 10th Annual Main Event ConferenceDaré Bioscience, Inc. to Present at the LD Micro 10th Annual Main Event Conference
finance.yahoo.com - December 4 at 8:52 AM
With An ROE Of 177.59%, Has Daré Bioscience Inc’s (DARE) Management Done A Good Job?With An ROE Of 177.59%, Has Daré Bioscience Inc’s (DARE) Management Done A Good Job?
finance.yahoo.com - November 30 at 5:49 PM
Daré Bioscience Inc (DARE): Is Healthcare Attractive Relative To NasdaqCM Peers?Daré Bioscience Inc (DARE): Is Healthcare Attractive Relative To NasdaqCM Peers?
finance.yahoo.com - October 20 at 7:17 PM
Contrasting Cerulean Pharma (DARE) & Dynavax Technologies Corporation (DVAX)Contrasting Cerulean Pharma (DARE) & Dynavax Technologies Corporation (DVAX)
www.americanbankingnews.com - October 15 at 12:10 AM
Daré Bioscience, Inc. to Present at the 2017 BIO Investor ForumDaré Bioscience, Inc. to Present at the 2017 BIO Investor Forum
finance.yahoo.com - October 10 at 3:30 PM
Daré Bioscience, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment ConferenceDaré Bioscience, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 7 at 5:48 PM
Daré Bioscience, Inc. to Present at the Liolios 6th Annual Gateway ConferenceDaré Bioscience, Inc. to Present at the Liolios 6th Annual Gateway Conference
finance.yahoo.com - August 30 at 6:51 PM
Cerulean Pharma Inc. (DARE) Given Consensus Rating of "Hold" by AnalystsCerulean Pharma Inc. (DARE) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - August 18 at 3:02 AM
Daré Bioscience, Inc. CEO Featured in San Diego Business Journal Article on Women FoundersDaré Bioscience, Inc. CEO Featured in San Diego Business Journal Article on Women Founders
finance.yahoo.com - August 15 at 6:30 PM
Daré Bioscience, Inc. Discusses Key Goals with Wall Street AnalyzerDaré Bioscience, Inc. Discusses Key Goals with Wall Street Analyzer
finance.yahoo.com - August 3 at 7:10 PM
Cerulean Pharma Inc. (DARE) Receives Average Recommendation of "Hold" from BrokeragesCerulean Pharma Inc. (DARE) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 24 at 11:58 AM
Daré Bioscience, Inc. announces Memorandum of Understanding with CONRAD for the conduct of the Ovaprene® postcoital test clinical trialDaré Bioscience, Inc. announces Memorandum of Understanding with CONRAD for the conduct of the Ovaprene® postcoital test clinical trial
finance.yahoo.com - July 24 at 10:42 AM

SEC Filings

Dare Bioscience (NASDAQ:DARE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dare Bioscience (NASDAQ:DARE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dare Bioscience (NASDAQ DARE) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.